7.1 million patients worldwide are remotely monitored, 2 million from ResMed alone
SAN DIEGO, Feb. 13, 2017 /CNW/ -- ResMed's global lead in remote patient monitoring kept growing in 2016, even as the industry itself continued to expand, according to the annual mHealth & Home Monitoring report released by independent technology analyst firm Berg Insight.
Roughly 7.1 million patients were remotely monitored by the end of 2016 on sleep, ventilator, diabetic, cardiovascular or other therapy, according to the mHealth report. That's up 45 percent from 4.9 million patients at the end of 2015.
"The number of remotely monitored sleep therapy patients grew by 70 percent in 2016," the report states, "with market growth mainly driven by the vendor ResMed that has made connected healthcare a cornerstone of its strategy."
"ResMed has been delivering on its promise to help streamline sleep therapy for patients and providers with digital solutions for over a decade, and we will continue to focus on connected care as we execute our growth strategy," said ResMed CEO Mick Farrell. "As the leading tech-driven medical device company, we have more than one billion nights of sleep data, and our digital health apps are clinically-proven to improve patient adherence. We strive every day to improve quality of life for patients, slow the progression of chronic disease and reduce the overall costs of our global healthcare system."
ResMed (NYSE: RMD) changes lives with award-winning medical devices and cutting-edge cloud-based software applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed is a global leader in connected care, with more than 2 million patients remotely monitored every day. Our 5,000-strong team is committed to creating the world's best tech-driven medical device company – improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 100 countries.
ResMed.com | Facebook | Twitter | LinkedIn
SOURCE ResMed Inc.